The Aroon Indicator for CNMD entered a downward trend on September 29, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 130 similar instances where the Aroon Indicator formed such a pattern. In of the 130 cases the stock moved lower. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on September 20, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on CNMD as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CNMD turned negative on September 21, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CNMD's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNMD advanced for three days, in of 327 cases, the price rose further within the following month. The odds of a continued upward trend are .
CNMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.998) is normal, around the industry mean (24.898). P/E Ratio (33.898) is within average values for comparable stocks, (79.320). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.382). Dividend Yield (0.008) settles around the average of (0.019) among similar stocks. P/S Ratio (2.761) is also within normal values, averaging (58.126).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CNMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a medical technology company, which provides surgical devices and equipment for minimally invasive procedures and monitoring
|ETFs / NAME||Price $||Chg $||Chg %|
|ETRACS Monthly Pay 1.5X Lvgd CE Fd ETN|
|iShares iBonds Dec 2026 Term Muni Bd ETF|
|Putnam ESG High Yield ETF|
|Goldman Sachs MarketBeta Emer Mkt Eq ETF|
|iShares U.S. Equity Factor ETF|
A.I.dvisor indicates that over the last year, CNMD has been loosely correlated with COO. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if CNMD jumps, then COO could also see price increases.
|advances in surgery|